Abstract
The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma treated with anti-CD20 monoclonal antibodies. Only 1 of 28 lymphoma patients (3.6%) developed a seropositive response, compared with 100% (28/28) of the healthy volunteers. The low levels of CD19 + lymphocytes among the lymphoma patients suggest that anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients once B cells are repopulated.
【초록키워드】 Efficacy, Vaccine, vaccination, pandemic, therapy, monoclonal antibodies, B cell, lymphocyte, lymphoma, Patient, death, Pfizer-BioNTech, seropositive, volunteers, anti-CD20, immunosuppressive, CD19, Non-Hodgkin Lymphoma, anti-CD20 treatment, Prevent, caused, indicated, treated, less, the vaccine, respond, the healthy, 【제목키워드】 Treatment, vaccination, monoclonal antibody, Patient, seropositive, Non-Hodgkin Lymphoma, inhibit,